• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

焦虑是接受肝动脉灌注化疗的伴有门静脉癌栓的肝细胞癌患者的一个风险预后因素:一项倾向评分匹配队列研究。

Anxiety is a risk prognosis factor for hepatocellular carcinoma with portal vein tumor thrombus who underwent hepatic arterial infusion chemotherapy: a propensity score-matching cohort study.

作者信息

Tan Hao-Yang, Liu Shuang-Quan, Liu Yan-Han, Lu Ling, Zheng Jiu-Ling, Feng Hua-Guo

机构信息

Department of Hepatobiliary Surgery, School of Medicine, The Chongqing University Jiangjin Hospital, Chongqing University, Chongqing, China.

Department of Radiology, School of Medicine, The Chongqing University Jiangjin Hospital, Chongqing University, Chongqing, China.

出版信息

World J Surg Oncol. 2025 May 14;23(1):189. doi: 10.1186/s12957-025-03845-8.

DOI:10.1186/s12957-025-03845-8
PMID:40369614
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12076914/
Abstract

BACKGROUND

Increasing evidence indicates that psychological factors play a role in tumor progression. This study aims to explore the impact of anxiety disorder on the prognosis of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) who underwent hepatic arterial infusion chemotherapy (HAIC).

METHODS

A propensity score-matching cohort study was conducted in 68 HCC patients with PVTT who underwent HAIC between January 2020 and December 2023. The anxiety situation was evaluated using the Hamilton Anxiety Rating Scale before HAIC. The objective response rate, overall survival (OS), progression-free survival, and adverse events were compared between the different anxiety score groups. Using Cox proportional hazards models for univariate and multivariate analysis to explore the risk factors of OS.

RESULTS

No statistical difference was found in the tumor response, treatment-related adverse events, and PFS between the two groups before and after PSM. Compared with low anxiety scores patients, the OS of obvious anxiety patients was shorter (hazard ratio [HR] = 1.606; 95%CI: 0.868-2.973; P = 0.116). The univariate and multivariate analysis showed that BMI (HR = 1.174, 95%CI: 1.044-1.320; P = 0.007), high anxiety score (HR = 2.769, 95%CI: 1.289-5.947; P = 0.007), and serum ammonia (HR = 1.059; 95%CI: 1.032-1.086; P < 0.001) were independent risk factors of OS.

CONCLUSIONS

Our study reveals that elevated anxiety scores in HCC patients with PVTT correlated with poor prognosis, indicating that it's a potential prognostic marker. The high anxiety score, BMI, and serum ammonia were independent risk factors of OS.

摘要

背景

越来越多的证据表明心理因素在肿瘤进展中起作用。本研究旨在探讨焦虑症对接受肝动脉灌注化疗(HAIC)的门静脉癌栓(PVTT)肝细胞癌(HCC)患者预后的影响。

方法

对2020年1月至2023年12月期间接受HAIC的68例PVTT-HCC患者进行倾向评分匹配队列研究。在HAIC前使用汉密尔顿焦虑量表评估焦虑情况。比较不同焦虑评分组之间的客观缓解率、总生存期(OS)、无进展生存期和不良事件。采用Cox比例风险模型进行单因素和多因素分析,以探讨OS的危险因素。

结果

PSM前后两组的肿瘤反应、治疗相关不良事件和PFS无统计学差异。与低焦虑评分患者相比,明显焦虑患者的OS较短(风险比[HR]=1.606;95%CI:0.868-2.973;P=0.116)。单因素和多因素分析显示,BMI(HR=1.174,95%CI:1.044-1.320;P=0.007)、高焦虑评分(HR=2.769,95%CI:1.289-5.947;P=0.007)和血清氨(HR=1.059;95%CI:1.032-1.086;P<0.001)是OS的独立危险因素。

结论

我们的研究表明,PVTT-HCC患者焦虑评分升高与预后不良相关,表明它是一个潜在的预后标志物。高焦虑评分、BMI和血清氨是OS的独立危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5ef/12076914/262525bb23d5/12957_2025_3845_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5ef/12076914/442286c4de36/12957_2025_3845_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5ef/12076914/262525bb23d5/12957_2025_3845_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5ef/12076914/442286c4de36/12957_2025_3845_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5ef/12076914/262525bb23d5/12957_2025_3845_Fig3_HTML.jpg

相似文献

1
Anxiety is a risk prognosis factor for hepatocellular carcinoma with portal vein tumor thrombus who underwent hepatic arterial infusion chemotherapy: a propensity score-matching cohort study.焦虑是接受肝动脉灌注化疗的伴有门静脉癌栓的肝细胞癌患者的一个风险预后因素:一项倾向评分匹配队列研究。
World J Surg Oncol. 2025 May 14;23(1):189. doi: 10.1186/s12957-025-03845-8.
2
Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.肝动脉灌注化疗联合卡瑞利珠单抗加瑞戈非尼治疗伴有门静脉癌栓的肝细胞癌:一项多中心倾向评分匹配分析。
Hepatol Int. 2024 Aug;18(4):1286-1298. doi: 10.1007/s12072-024-10672-8. Epub 2024 May 8.
3
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.系统评价肝动脉灌注化疗与索拉非尼治疗合并门静脉癌栓的肝细胞癌患者的疗效。
J Gastroenterol Hepatol. 2020 Aug;35(8):1277-1287. doi: 10.1111/jgh.15010. Epub 2020 Mar 3.
4
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion.肝动脉灌注化疗联合仑伐替尼和替雷利珠单抗治疗伴Vp4门静脉侵犯的晚期肝细胞癌
Hepatol Int. 2025 Feb;19(1):106-117. doi: 10.1007/s12072-024-10762-7. Epub 2025 Jan 9.
5
Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.经动脉化疗栓塞联合肝动脉灌注化疗与单纯经动脉化疗栓塞治疗合并门静脉癌栓肝细胞癌的疗效比较:倾向评分匹配分析。
Biomed Res Int. 2021 Jul 14;2021:6670367. doi: 10.1155/2021/6670367. eCollection 2021.
6
Similar Efficacy Between Atezolizumab Plus Bevacizumab Hepatic Arterial Infusion Chemotherapy For Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Cohort Study.贝伐珠单抗联合阿替利珠单抗肝动脉灌注化疗治疗不可切除肝细胞癌伴门静脉癌栓的疗效比较:一项回顾性队列研究。
In Vivo. 2024 Jul-Aug;38(4):1854-1858. doi: 10.21873/invivo.13639.
7
Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.乐伐替尼联合载药微球经动脉化疗栓塞术联合或不联合肝动脉灌注化疗治疗直径大于7cm且伴有主要门静脉肿瘤血栓形成的肝细胞癌:一项多中心回顾性队列研究
Int J Surg. 2024 Dec 1;110(12):7860-7870. doi: 10.1097/JS9.0000000000001819.
8
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.随机、前瞻性、比较研究索拉非尼与肝动脉灌注化疗治疗伴有门静脉癌栓的晚期肝细胞癌的疗效和安全性。
Cancer Chemother Pharmacol. 2018 Sep;82(3):469-478. doi: 10.1007/s00280-018-3638-0. Epub 2018 Jul 7.
9
Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score-matching cohort study.经门静脉侵犯的肝细胞癌肝动脉灌注奥沙利铂联合雷替曲塞和化疗栓塞:一项倾向评分匹配队列研究。
J Surg Oncol. 2022 Dec;126(7):1205-1214. doi: 10.1002/jso.27023. Epub 2022 Jul 20.
10
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.肝动脉灌注化疗治疗伴有门静脉癌栓的晚期肝细胞癌:48例分析
Cancer. 2002 Aug 1;95(3):588-95. doi: 10.1002/cncr.10694.

本文引用的文献

1
SLC4A11 mediates ammonia import and promotes cancer stemness in hepatocellular carcinoma.SLC4A11 介导氨的摄取并促进肝癌中的癌症干细胞特性。
JCI Insight. 2024 Nov 8;9(21):e184826. doi: 10.1172/jci.insight.184826.
2
Psychiatric disorders in patients with hepatocellular carcinoma: A large US cohort of commercially insured individuals.肝细胞癌患者的精神障碍:一项大型美国商业保险个体队列研究。
Aliment Pharmacol Ther. 2024 Aug;60(4):469-478. doi: 10.1111/apt.18115. Epub 2024 Jun 11.
3
Ammonia is associated with liver-related complications and predicts mortality in acute-on-chronic liver failure patients.
氨与肝相关并发症相关,并可预测慢加急性肝衰竭患者的死亡率。
Sci Rep. 2024 Mar 9;14(1):5796. doi: 10.1038/s41598-024-56401-x.
4
Factors affecting anxiety, depression, and stress among patients with hepatocellular carcinoma during COVID-19 pandemic.影响 COVID-19 大流行期间肝细胞癌患者焦虑、抑郁和压力的因素。
Eur Rev Med Pharmacol Sci. 2023 Jan;27(2):704-712. doi: 10.26355/eurrev_202301_31073.
5
Glutamine synthetase limits β-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1.谷氨酰胺合成酶通过维持氮平衡和抑制 mTORC1 来限制β-链脲佐菌素诱导的肝癌生长。
J Clin Invest. 2022 Dec 15;132(24):e161408. doi: 10.1172/JCI161408.
6
Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events.将欧洲癌症研究与治疗组织项目库链接到常见不良事件术语标准。
J Clin Oncol. 2022 Nov 10;40(32):3770-3780. doi: 10.1200/JCO.21.02017. Epub 2022 Aug 16.
7
Ammonia stimulates SCAP/Insig dissociation and SREBP-1 activation to promote lipogenesis and tumour growth.氨刺激 SCAP/Insig 解离和 SREBP-1 激活,促进脂肪生成和肿瘤生长。
Nat Metab. 2022 May;4(5):575-588. doi: 10.1038/s42255-022-00568-y. Epub 2022 May 9.
8
Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy.门静脉癌栓型肝细胞癌的治疗:现状与争议
J Clin Transl Hepatol. 2022 Feb 28;10(1):147-158. doi: 10.14218/JCTH.2021.00179. Epub 2021 Aug 10.
9
A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus.一种用于伴有门静脉癌栓的肝细胞癌的新分期系统。
Hepatobiliary Surg Nutr. 2021 Dec;10(6):782-795. doi: 10.21037/hbsn-19-810.
10
The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.门静脉癌栓型肝细胞癌的治疗进展
Front Oncol. 2021 Sep 23;11:635731. doi: 10.3389/fonc.2021.635731. eCollection 2021.